Abstract
The Journal of Sexual Medicine (JSM) was developed on the premise that the sexual health of men and women is equally important. For men with sexual dysfunction, there are currently multiple pharmaceutical products approved by various government regulation agencies around the world [1]. The first, intracavernosal alprostadil, was approved in 1996, a decade ago. Presently, the list of pharmaceutical options for men with sexual health concerns includes two versions of intracavernosal alprostadil, intraurethral alprostadil, three different oral phosphodiesterase type 5 agents [2–4], and sublingual apomorphine for a total of seven pharmaceutical applications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
